Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The submission of the first 'smart pill' for market approval, combined with progress in the European nanomedicine landscape, illustrates the positive outlook for drug therapy and health monitoring, explains Christian Martin.
The relationship between technology and religion is diverse and nuanced, but understanding it can be a valuable intellectual exercise, as Chris Toumey explains.
For DNA nanodevices to be deployed in living cells and higher organisms, they need to be biocompatible and inexpensive enough to be produced in large quantities.
If emerging technologies such as nanotechnology are to reach their full potential we need to radically change our approach to risk, argues Andrew D. Maynard.